Terms: = Lymphoma AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
1658 results:
1. IL-15 gene mutation as a molecular risk factor in acute lymphoid leukemia.
Mohammed SI; Hassan KM; Azeez DM; Qadir FA; Salihi AB
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):10-17. PubMed ID: 38814240
[TBL] [Abstract] [Full Text] [Related]
2. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract] [Full Text] [Related]
3. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
[TBL] [Abstract] [Full Text] [Related]
5. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H; von Itzstein MS; Fattah F; Liu J; Zhu C; Xie Y; Wakeland EK; Park JY; Kahl BS; Diefenbach CS; Gerber DE
Oncoimmunology; 2024; 13(1):2351255. PubMed ID: 38737792
[TBL] [Abstract] [Full Text] [Related]
6. Frequency and Aberrant CD Marker Profile of Acute Leukaemias.
Arshad MZ; Hassan MA; Bibi M; Hussain M; Alam M; Riaz MO
J Coll Physicians Surg Pak; 2024 May; 34(5):539-544. PubMed ID: 38720213
[TBL] [Abstract] [Full Text] [Related]
7. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
[TBL] [Abstract] [Full Text] [Related]
8. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell lymphoma.
Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
[TBL] [Abstract] [Full Text] [Related]
9. Identification of a prognostic signature based on five ferroptosis-related genes for diffuse large B-cell lymphoma.
Li W; Yao R; Yu N; Zhang W
Cancer Biomark; 2024; 40(1):125-139. PubMed ID: 38517778
[TBL] [Abstract] [Full Text] [Related]
10. Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
Han L; Xing H; Cao W; Song Y; Jiang Z; Yu J
Expert Opin Biol Ther; 2024 Apr; 24(4):221-223. PubMed ID: 38506624
[TBL] [Abstract] [Full Text] [Related]
11. Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J; Cheng S; Gao X; Yu SH; Dai YT; Huang XY; Zhong HJ; Wang CF; Yi HM; Zhang H; Cao WG; Li R; Tang W; Zhao Y; Xu PP; Wang L; Zhao WL
Signal Transduct Target Ther; 2024 Mar; 9(1):62. PubMed ID: 38448403
[TBL] [Abstract] [Full Text] [Related]
12. A novel β-cyclodextrin-assisted enhancement strategy for portable and sensitive detection of miR-21 in human serum.
Yao F; Wu L; Xiong Y; Su C; Guo Y; Bulale S; Zhou M; Tian Y; He L
Anal Methods; 2024 Mar; 16(11):1639-1648. PubMed ID: 38414387
[TBL] [Abstract] [Full Text] [Related]
13. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract] [Full Text] [Related]
14. Similar geographic distribution of mortality from multiple sclerosis, Hodgkin lymphoma, and inflammatory bowel disease in the United States.
Sonnenberg A
Mult Scler Relat Disord; 2024 Apr; 84():105493. PubMed ID: 38354444
[TBL] [Abstract] [Full Text] [Related]
15. An anti-CD19/ctla-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.
Prinz LF; Riet T; Neureuther DF; Lennartz S; Chrobok D; Hübbe H; Uhl G; Riet N; Hofmann P; Hösel M; Simon AG; Tetenborg L; Segbers P; Shimono J; Gödel P; Balke-Want H; Flümann R; Knittel G; Reinhardt HC; Scheid C; Büttner R; Chapuy B; Ullrich RT; Hallek M; Chmielewski MM
Cell Rep Med; 2024 Feb; 5(2):101421. PubMed ID: 38340727
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Characteristics and Local Histopathological Modulators of Endometriosis and Its Progression.
Istrate-Ofiţeru AM; Mogoantă CA; Zorilă GL; Roşu GC; Drăguşin RC; Berbecaru EI; Zorilă MV; Comănescu CM; Mogoantă SȘ; Vaduva CC; Brătilă E; Iliescu DG
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339066
[TBL] [Abstract] [Full Text] [Related]
17. Automated classification of ulcerative lesions in small intestine using densenet with channel attention and residual dilated blocks.
Guo X; Xu L; Liu Z; Hao Y; Wang P; Zhu H; Du Y
Phys Med Biol; 2024 Feb; 69(5):. PubMed ID: 38316034
[No Abstract] [Full Text] [Related]
18. A case report: Castleman disease treated by the trinity of internal and external treatment of "Fuzheng, phlegm-resolving, and detoxification method".
Yuan X; Fu H; Xu M; Shen W; Zhou W; Li X; Gan X
Medicine (Baltimore); 2024 Feb; 103(5):e37110. PubMed ID: 38306555
[TBL] [Abstract] [Full Text] [Related]
19. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Pirosa MC; Stathis A; Zucca E
Hum Vaccin Immunother; 2024 Dec; 20(1):2309701. PubMed ID: 38299612
[TBL] [Abstract] [Full Text] [Related]
20. Therapy of Castleman's disease with siltuximab - case report and review of literature.
Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
[TBL] [Abstract] [Full Text] [Related]
[Next]
